E Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

E Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$415K	Sell	7,246 -2,390	-25%	-$131K	0.01%	319
2026 Q1	$544K	Buy	+9,636	New	+$562K	0.02%	277
2025 Q2	$1.03M	Buy	18,772 +6,534	+53%	+$385K	0.05%	166
2025 Q1	$865K	Sell	12,238 -2,224	-15%	-$150K	0.04%	182
2024 Q4	$951K	Buy	14,462 +1,666	+13%	+$112K	0.05%	150
2024 Q3	$899K	Sell	12,796 -684	-5%	-$57.2K	0.05%	152
2024 Q2	$1.11M	Buy	13,480 +8,438	+167%	+$702K	0.06%	118
2024 Q1	$440K	Sell	5,042 -126	-2%	-$11.3K	0.03%	182
2023 Q4	$498K	Buy	5,168 +98	+2%	+$8.67K	0.03%	170
2023 Q3	$449K	Buy	5,070 +181	+4%	+$16.1K	0.03%	142
2023 Q2	$424K	Buy	4,889 +621	+15%	+$58.4K	0.03%	152
2023 Q1	$415K	Buy	4,268 +137	+3%	+$14.2K	0.03%	152
2022 Q4	$428K	Sell	4,131 -995	-19%	-$93.4K	0.04%	167
2022 Q3	$435K	Sell	5,126 -706	-12%	-$62.9K	0.04%	161
2022 Q2	$483K	Buy	5,832 +2,301	+65%	+$183K	0.04%	146
2022 Q1	$272K	Buy	+3,531	New	+$295K	0.01%	232

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

E Fund Management's BMRN Position: Q2 2026 in Review

E Fund Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 25% in Q2 2026, selling an estimated $131K and leaving 7,246 shares worth $415K. The position accounts for 0.01% of the portfolio, ranked #319.

E Fund Management first reported a position in BMRN in Q1 2022 and has held it in 16 quarters since. The position peaked at $1.11M in Q2 2024. 562 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

E Fund Management held 7,246 shares of BioMarin Pharmaceuticals worth $415K as of Q2 2026.
E Fund Management sold 2,390 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $131K.
BioMarin Pharmaceuticals made up 0.01% of E Fund Management's portfolio in Q2 2026, its #319 holding.
E Fund Management first reported a position in BioMarin Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
E Fund Management's BioMarin Pharmaceuticals position peaked at $1.11M in Q2 2024.
562 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.